TOP1 and breast neoplasm: Anti-miR-21 sensitized breast tumour cells to topotecan (i.e., an inhibitor of DNA topoisomerase I), suggesting that suppression of oncogenic miR-21 sensitized breast tumour cells to topotecan10.